Skip to main content

Adjuvant Grade II or III Meningioma JZP3507-202

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • San Francisco
  • San Mateo
  • Vallejo
  • Palo Alto

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma

Akanksha Sharma, M.D.
Akanksha Sharma, M.D.
Principal investigator
View profile

Sub-Investigators

Julian H McLain, M.D., Lewis Z Leng, M.D., FAANS, Roozbeh Mohajer, M.D., Al V Taira, M.D., Michael Y Zhang, M.D., PhD, Patricia L Seid, M.D.

Related clinical trials

View all clinical trials
  • Clinical trial

    Residual, Progressive or Recurrent Grade II or III Meningioma NEO100-02

    An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma

    Status: Open to Enrollment

  • Clinical trial

    Advanced Cervical Cancer NRG GY037

    A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

    Status: Open to Enrollment

  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB

    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?